Stemline Therapeutics Inc. (STML) Given Buy Rating at Roth Capital
Roth Capital reaffirmed their buy rating on shares of Stemline Therapeutics Inc. (NASDAQ:STML) in a report published on Wednesday. The firm currently has a $32.00 price target on the biopharmaceutical company’s stock.
Several other equities research analysts have also recently weighed in on the company. HC Wainwright restated a buy rating on shares of Stemline Therapeutics in a research note on Monday. Zacks Investment Research cut Stemline Therapeutics from a hold rating to a sell rating in a research note on Friday, November 11th. Wedbush restated an outperform rating and set a $15.00 target price on shares of Stemline Therapeutics in a research note on Tuesday, November 8th. Finally, Jefferies Group restated a buy rating on shares of Stemline Therapeutics in a research note on Friday, August 5th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $20.50.
Shares of Stemline Therapeutics (NASDAQ:STML) remained flat at $13.65 during trading on Wednesday. The company had a trading volume of 99,549 shares. Stemline Therapeutics has a one year low of $3.88 and a one year high of $14.20. The company’s market capitalization is $243.60 million. The company’s 50-day moving average is $12.11 and its 200 day moving average is $8.87.
Hedge funds have recently bought and sold shares of the stock. Emerald Acquisition Ltd. purchased a new stake in Stemline Therapeutics during the second quarter valued at $129,000. Oak Ridge Investments LLC raised its stake in Stemline Therapeutics by 26.3% in the third quarter. Oak Ridge Investments LLC now owns 12,796 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 2,663 shares during the period. Paradigm Asset Management Co. LLC purchased a new stake in Stemline Therapeutics during the second quarter valued at $141,000. Nationwide Fund Advisors raised its stake in Stemline Therapeutics by 63.2% in the second quarter. Nationwide Fund Advisors now owns 22,395 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 8,670 shares during the period. Finally, Rhumbline Advisers raised its stake in Stemline Therapeutics by 20.9% in the second quarter. Rhumbline Advisers now owns 26,260 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 4,538 shares during the period. 49.23% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Stemline Therapeutics Inc. (STML) Given Buy Rating at Roth Capital” was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/24/stemline-therapeutics-inc-stml-given-buy-rating-at-roth-capital.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.